These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11563596)

  • 21. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
    Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
    Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of lamivudine in the reactivation of hepatitis B virus infection in immunodepressed patients.
    Martín E; Rendón P; De Diego L; Soria MJ; Martínez MC; Martín L
    Rev Esp Enferm Dig; 2003 Nov; 95(11):804-8, 799-803. PubMed ID: 14640878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma.
    Enomoto M; Nishiguchi S; Seki S; Yamane T; Hino M
    Am J Gastroenterol; 2004 Aug; 99(8):1619-20. PubMed ID: 15307884
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
    Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
    Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.
    Yilmaz M; Dagdas S; Güler N; Aki SZ; Aköz AG; Özet G; Ayli M; Saritas U
    Hematology; 2003 Dec; 8(6):393-6. PubMed ID: 14668034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab.
    Hamaki T; Kami M; Kusumi E; Ueyama J; Miyakoshi S; Morinaga S; Mutou Y
    Am J Hematol; 2001 Dec; 68(4):292-4. PubMed ID: 11754421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
    Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients.
    Lin PC; Poh SB; Lee MY; Hsiao LT; Chen PM; Chiou TJ
    Int J Hematol; 2005 May; 81(4):349-51. PubMed ID: 15914368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma.
    Ozguroglu M; Bilici A; Turna H; Serdengecti S
    Med Oncol; 2004; 21(1):67-72. PubMed ID: 15034216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation.
    Uchida N; Gondo H; Himeji D; Kaji Y; Sata M; Niho Y
    Bone Marrow Transplant; 2000 Dec; 26(11):1243-5. PubMed ID: 11149741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
    Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
    Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
    Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
    Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.
    Liu CJ; Lai MY; Lee PH; Chou NK; Chu SH; Chen PJ; Kao JH; Jen YM; Chen DS
    J Gastroenterol Hepatol; 2001 Sep; 16(9):1001-8. PubMed ID: 11595064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.